Product Images Eysuvis

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Eysuvis NDC 71571-333 by Alcon Laboratories, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Chemical Structure - eysuvis 01

Chemical Structure - eysuvis 01

Figure 1 - eysuvis 02

Figure 1 - eysuvis 02

This appears to be a table summarizing some numerical data from four studies related to vehicle and EVSUVIS differences. Each study seems to have multiple visits with a certain number of participants (N) and a baseline value. Additionally, for each visit there are values for EVSUVIS, a difference value, and a confidence interval. More information is needed to provide a more comprehensive description.*

Figure 2 - eysuvis 03

Figure 2 - eysuvis 03

Figure A - eysuvis 04

Figure A - eysuvis 04

Figure B - eysuvis 05

Figure B - eysuvis 05

Figure C - eysuvis 06

Figure C - eysuvis 06

Figure D - eysuvis 07

Figure D - eysuvis 07

Figure E - eysuvis 08

Figure E - eysuvis 08

Figure F - eysuvis 09

Figure F - eysuvis 09

Bottle Label - eysuvis 10

Bottle Label - eysuvis 10

This is a description of a prescription medication with the NDC number 71571-333-83 called "EYSuvIS". It is an ophthalmic suspension containing 0.25% of the active ingredient, ioteprednol etabonate. The medication comes in a sterile 8.3 mL container and is intended for topical application in the eye. The dosage information is included in the package insert. The medication is manufactured by Kala Pharmaceuticals in Watertown, MA.*

Carton Label - eysuvis 11

Carton Label - eysuvis 11

EYSUVIS™ Ophthalmic Suspension is a medication used for topical application in the eye. The active ingredient is loteprednol etabonate 2.5 mg (0.25%) and the inactive components include glycerin, sodium citrate dihydrate, sodium chloride, Poloxamer 407, edetate disodium dihydrate, citric acid, and water for injection. The medication is produced by Kala Pharmaceuticals Inc. and should be stored upright at 15°C to 25°C (59°F to 77°F). The tamper-evident overcap should be intact before use. The dosage details are present in the package insert.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.